0000921895-21-002138.txt : 20210817
0000921895-21-002138.hdr.sgml : 20210817
20210817180715
ACCESSION NUMBER: 0000921895-21-002138
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210813
FILED AS OF DATE: 20210817
DATE AS OF CHANGE: 20210817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Myrexis, Inc.
CENTRAL INDEX KEY: 0001459450
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12957
FILM NUMBER: 211184403
BUSINESS ADDRESS:
STREET 1: 600 FIFTH AVENUE, 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10020
BUSINESS PHONE: 801-214-7800
MAIL ADDRESS:
STREET 1: 600 FIFTH AVENUE, 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10020
FORMER NAME:
FORMER CONFORMED NAME: Myriad Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20090324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COUCHMAN JONATHAN
CENTRAL INDEX KEY: 0001265094
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12957
FILM NUMBER: 211184406
MAIL ADDRESS:
STREET 1: 630 FIFTH AVENUE
STREET 2: SUITE 2260
CITY: NEW YORK
STATE: NY
ZIP: 10020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Couchman Family Fund
CENTRAL INDEX KEY: 0001737322
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12957
FILM NUMBER: 211184405
BUSINESS ADDRESS:
STREET 1: 630 FIFTH AVENUE, SUITE 2260
CITY: NEW YORK
STATE: NY
ZIP: 10020
BUSINESS PHONE: (212) 729-4962
MAIL ADDRESS:
STREET 1: 630 FIFTH AVENUE, SUITE 2260
CITY: NEW YORK
STATE: NY
ZIP: 10020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Xstelos Corp.
CENTRAL INDEX KEY: 0001571659
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12957
FILM NUMBER: 211184404
BUSINESS ADDRESS:
STREET 1: 630 FIFTH AVENUE
STREET 2: SUITE 2260
CITY: NEW YORK
STATE: NY
ZIP: 10020
BUSINESS PHONE: 212.729.4962
MAIL ADDRESS:
STREET 1: 630 FIFTH AVENUE
STREET 2: SUITE 2260
CITY: NEW YORK
STATE: NY
ZIP: 10020
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000727510
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 222372868
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 20 COMMERCE DRIVE, SUITE 135
CITY: CRANFORD
STATE: NJ
ZIP: 07016
BUSINESS PHONE: 732-980-4500
MAIL ADDRESS:
STREET 1: 20 COMMERCE DRIVE, SUITE 135
CITY: CRANFORD
STATE: NJ
ZIP: 07016
FORMER COMPANY:
FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060324
FORMER COMPANY:
FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20021211
FORMER COMPANY:
FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20021210
4
1
form405735004_08172021.xml
OWNERSHIP DOCUMENT
X0306
4
2021-08-13
0
0000727510
ENZON PHARMACEUTICALS, INC.
ENZN
0001265094
COUCHMAN JONATHAN
600 FIFTH AVENUE
2ND FLOOR
NEW YORK
NY
10020
0
0
1
0
0001737322
Couchman Family Fund
600 FIFTH AVENUE
2ND FLOOR
NEW YORK
NY
10020
0
0
1
0
0001571659
Xstelos Corp.
600 FIFTH AVENUE
2ND FLOOR
NEW YORK
NY
10020
0
0
1
0
0001459450
Myrexis, Inc.
600 FIFTH AVENUE
2ND FLOOR
NEW YORK
NY
10020
0
0
1
0
Common Stock, $0.01 par value
4717666
I
By Jonathan Couchman
Common Stock, $0.01 par value
2021-08-13
4
S
0
50000
0.3898
D
350000
I
By Couchman Family Fund
Common Stock, $0.01 par value
2021-08-13
4
S
0
57500
0.3898
D
2043024
I
By Xstelos Corp.
Common Stock, $0.01 par value
633264
I
By Myrexis, Inc.
This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis") (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
Represents shares owned directly by Mr. Couchman. As the sole trustee of the Foundation, Mr. Couchman may be deemed to beneficially own the Shares owned by the Foundation. As the Chief Executive Officer of Xstelos, Mr. Couchman may be deemed to beneficially own the shares of Common Stock owned by Xstelos. As the Chief Executive Officer of Myrexis, Mr. Couchman may be deemed to beneficially own Shares of Common Stock owned by Myrexis.
Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions and the reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commision, upon request, full information regarding the number of shares purchased at each separate price.
Effective September 17, 2020, Michael Pearce, Brian Harper and Harper Asset Management, LLC ceased to be members of the Section 13(d) group and ceased to be Reporting Persons.
/s/ Jonathan Couchman
2021-08-17
Couchman Family Fund; By: /s/ Jonathan Couchman, Trustee
2021-08-17
Xstelos Corp.; By: /s/ Jonathan Couchman, Chief Executive Officer
2021-08-17
Myrexis, Inc.; By: /s/ Jonathan Couchman, Chief Executive Officer
2021-08-17